SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 77763.91
261.79 (0.34%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Nectar Lifesciences Ltd.	Q V PT	230 Small Cap	11.85 (0.00%)	N/A	0.4	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Fabtech Technologies Ltd.	Q V PT	738 Small Cap	166.10 (2.69%)	29.65	1.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Anuh Pharma Ltd.	Q V PT	804 Small Cap	80.21 (-1.57%)	19.9	2.32	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Sigachi Industries Ltd.	Q V+ PT	861 Small Cap	22.54 (-2.00%)	N/A	1.85	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Shree Ganesh Remedies Ltd.	Q V PT	865 Small Cap	673.90 (4.90%)	46.4	5.06	13.20	20.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Kopran Ltd.	Q V PT	939 Small Cap	194.55 (4.07%)	29.69	2.02	8.61	14.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Health X Platform Ltd.	Q V PT	993 Small Cap	311 (0.00%)	N/A	3.65	109.54	-201.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Wanbury Ltd.	Q V+ PT	1,003 Small Cap	287.20 (0.12%)	15.15	6.94	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	3B Blackbio Dx Ltd.	Q V PT	1,006 Small Cap	1,172.50 (-2.92%)	21.02	3.8	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Fermenta Biotech Ltd.	Q V PT	1,018 Small Cap	345.85 (-1.45%)	16.07	2.44	7.46	0.93	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Gujarat Kidney And Super Speciality Ltd.	Q V+ PT	1,024 Small Cap	129.90 (-0.84%)	104.32	4.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Themis Medicare Ltd.	Q V PT	1,091 Small Cap	118.45 (-0.59%)	N/A	4.09	15.00	7.68	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Bajaj Healthcare Ltd.	Q V PT	1,161 Small Cap	344.75 (0.75%)	54.06	2.16	5.76	2.91	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Lincoln Pharmaceuticals Ltd.	Q V PT	1,242 Small Cap	620.05 (-0.86%)	14.25	1.65	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Laxmi Dental Ltd.	Q V PT	1,254 Small Cap	228.10 (1.45%)	75.23	5	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	GPT Healthcare Ltd.	Q V PT	1,301 Small Cap	158.55 (1.34%)	30.41	4.76	13.96	24.04	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Syncom Formulations (India) Ltd.	Q V PT	1,338 Small Cap	14.23 (-0.14%)	17.62	3.25	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Tarsons Products Ltd.	Q V+ PT	1,412 Small Cap	265.45 (-0.23%)	62.47	2.1	12.30	-1.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Suraksha Diagnostic Ltd.	Q V PT	1,425 Small Cap	273.60 (0.85%)	43.9	5.77	9.86	-51.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Jagsonpal Pharmaceuticals Ltd.	Q V+ PT	1,554 Small Cap	236.05 (0.36%)	35.94	6.52	11.13	39.15	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Windlas Biotech Ltd.	Q V PT	1,799 Small Cap	871.70 (1.20%)	26.76	3.33	16.15	15.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Krsnaa Diagnostics Ltd.	Q V+ PT	1,822 Small Cap	561.70 (-1.90%)	18.31	1.89	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Shalby Ltd.	Q V PT	1,862 Small Cap	172.35 (-0.63%)	16.59	1.5	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Hester Biosciences Ltd.	Q V PT	1,879 Small Cap	2,208.85 (1.39%)	35.57	4.81	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	KMC Speciality Hospitals (India) Ltd.	Q V PT	2,180 Small Cap	133.65 (0.04%)	N/A	N/A	19.21	12.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Indoco Remedies Ltd.	Q V+ PT	2,257 Small Cap	244.55 (0.49%)	N/A	2.04	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,432 Small Cap	5,033.05 (-1.43%)	35.2	7.13	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Fischer Medical Ventures Ltd.	Q V PT	2,573 Small Cap	39.31 (0.59%)	N/A	8.19	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Vimta Labs Ltd.	Q V+ PT	2,616 Small Cap	585.35 (-0.13%)	33.79	5.82	14.27	28.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Hikal Ltd.	Q V+ PT	2,740 Small Cap	222.20 (-0.43%)	N/A	2.3	4.29	-1.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Suven Life Sciences	327.55	9.68%
Shree Ganesh Remed.	673.90	4.90%
Piramal Pharma	175.90	4.58%
Dishman Carbogen Amc	196.60	4.57%
Kopran	194.55	4.07%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Rubicon Research	1,302.75	-5.22%
IOL Chem & Pharma	143.05	-4.76%
Bliss GVS Pharma	506.15	-3.87%
Poly Medicure	1,680.05	-3.32%
3B Blackbio Dx	1,172.50	-2.92%

News about Top Pharma Companies in India

Jul, 2026

Fabtech Technologies informs about outcome of postal ballot

Fabtech Technologies has informed that the Company had sought consent from members of the Company on the following resolutions through Postal Ballot notice dated May 25, 2026: Appointment of Rupal Dhiren Haria (DIN: 10624643) as a Non-Executive Independent Director of the Company; and Appointment of Bharti Khanna (DIN: 05147844) as a Non-Executive Independent Director of the Company. Based on the report issued by our Scrutinizer, CS Rachana Shanbhag, Partner of DA Kamat & Co., Company Secretaries, (FCS: 8227/ CP: 9297), the above resolutions have been passed and the same are deemed to have been approved on the last date of e-voting period i.e., Tuesday, June 30, 2026. The voting results in the format prescribed under Regulation 44(3) of SEBI. Listing. Regulations, along with the Scrutinizer's Report on remote e-voting, in respect of above resolutions are attached. The Voting Results along with the Scrutinizer's Report are available on the Company's website www.fabtechnologies.com and also on the website of NSDL at https://www.evoting.nsdl.com/.

The above information is a part of company's filings submitted to BSE.

Jul, 2026

Themis Medicare informs about disclosure

Themis Medicare has informed that the exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for CTL Trusteeship.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Windlas Biotech submits AGM notice

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) read with Schedule III of the said Regulations, Windlas Biotech has informed that it enclosed a copy of the Notice of the 25th Annual General Meeting (AGM) of the Company scheduled to be held on Thursday, July 23, 2026 at 01.00 PM (IST) through Video Conferencing (VC)/Other Audio ,Visual Means (OAVM), in accordance with the relevant circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India. ln compliance with the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the Listing Regulations, the Company is pleased to provide to its Members, facility to exercise their right to vote at the 25th AGM scheduled to be held on July 23, 2026, by electronic means and the business mentioned in the AGM Notice may be transacted through e-voting services provided by MUFG Intime India at https://instavote.linkintime.co.in/. The Company has fixed July 16, 2026 as the ‘cut-off date’ for ascertaining the names of members, holding shares of the Company, who will be entitled to cast their votes electronically during July 20, 2026 (9:00 AM) to July 22, 2026 (5:00 PM) and also during AGM in respect of business to be transacted at the aforesaid AGM and for the purpose of receiving dividend, if any.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Vimta Labs informs about closure of trading window

Vimta Labs has informed that as per the provisions of the Company’s code of conduct for prevention of Insider Trading, the Trading Window for transactions in shares of the Company for all designated persons, their immediate relatives and all connected persons under the code will remain closed from 1stJuly 2026 till 48 hours post declaration of unaudited financial results of the Company for the first quarter ended 30th June 2026.

The above information is a part of company’s filings submitted to BSE.

Jun, 2026

Jagsonpal Pharma inks definitive pact to acquire 85% equity stake in Aequitas

The total consideration for 85% stake would be Rs 20.8 crore, which shall be funded from internal accruals of the company

Jun, 2026

Tarsons Products informs about trading window closure

Tarsons Products has informed that in terms of the Company’s Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, read with SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in the securities of Tarsons Products (the Company) will remain closed for all Designated Persons and their immediate relatives with effect from Wednesday, July 01, 2026 until 48 hours after the declaration and dissemination of the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026. Accordingly, all the Designated Persons have been intimated not to trade in the securities of the Company during the aforesaid period of closure of the Trading Window.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	230 Crore
2	Fabtech Technologies Ltd.	738 Crore
3	Anuh Pharma Ltd.	804 Crore
4	Sigachi Industries Ltd.	861 Crore
5	Shree Ganesh Remedies Ltd.	865 Crore
6	Kopran Ltd.	939 Crore
7	Health X Platform Ltd.	993 Crore
8	Wanbury Ltd.	1,003 Crore
9	3B Blackbio Dx Ltd.	1,006 Crore
10	Fermenta Biotech Ltd.	1,018 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	25,850	54,930	35.39	11.51	24.16	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,766	1,61,290	74.55	19.23	39.18	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,326	41,550	39.35	9.18	26.59	25.35
Lupin Ltd. (M)	Somewhat Good	2,476	1,13,215	21.23	5.04	12.28	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,141	1,13,815	22.58	4.38	13.82	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,542	83,293	103
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,363	37,944	44.17
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,766	1,61,290	42.84
Aurobindo Pharma Ltd. (M)	Very Good	1,620	93,217	40.20
Gland Pharma Ltd. (S)	Very Good	2,461	40,588	31.30
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,363	37,944	56.29	9.40	34.09	15.51
Mankind Pharma Ltd. (M)	Very Good	2,531	1,04,535	51.30	6.38	32.20	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,326	41,550	39.35	9.18	26.59	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,375	1,14,730	27.34	3.04	15.25	12.09
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,766	1,61,290	74.55	19.23	39.18	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,141	1,13,815	22.58	4.38	13.82	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,905	4,56,989	39.81	5.47	22.81	23.50
Abbott India Ltd. (M)	Very Good	25,850	54,930	35.39	11.51	24.16	18.78
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,375	1,14,730	27.34	3.04	15.25	15.75
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,210	62,362	45.79	5.93	12.16	14.41

You have 7 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Fabtech Technologies informs about outcome of postal ballot

Themis Medicare informs about disclosure

Windlas Biotech submits AGM notice

Vimta Labs informs about closure of trading window

Jagsonpal Pharma inks definitive pact to acquire 85% equity stake in Aequitas

Tarsons Products informs about trading window closure

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.